Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Updates in Melanoma From ASCO
9+ hour, 28+ min ago (379+ words) Meredith McKean, MD, MPH, of Sarah Cannon Research Institute in Nashville, Tennessee, shares commentary on updates in melanoma presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Meredith McKean, MD, MPH: Hi, I am Meredith McKean. I’m a…...
Updates to Merkel Cell Carcinoma From ASCO
9+ hour, 28+ min ago (320+ words) Meredith McKean, MD, MPH, of Sarah Cannon Research Institute in Nashville, Tennessee, shares commentary on updates to Merkel cell carcinoma (MCC) presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. McKean describes updates from the STAMP, ADAM, and…...
Biparatopic HER2 Targeting in Action: Anbenitamab???s Phase 3 Breakthrough
9+ hour ago (38+ words) Biparatopic HER2 Targeting in Action: Anbenitamab’s Phase 3 Breakthrough Docwire News Biparatopic HER2 Targeting in Action: Anbenitamab’s Phase 3 Breakthrough Shao ZM, et al. Basch E, et al. 2026 American Society of Clinical Oncology Annual Meeting. Abstract LBA660....
Public Policy: How to Get Involved
8+ hour, 29+ min ago (789+ words) Docwire News Public Policy: How to Get Involved To kick off 2026, Anna Gaddy, MD, of the Nephrology Times editorial board and the Medical College of Wisconsin wanted to explore the role of public policy in nephrology. Following a conversation with…...
Practice Management for Dermatologists
9+ hour, 33+ min ago (553+ words) Roman Bronfenbrener, MD, from Pennsylvania Dermatology Specialists and University of Pennsylvania, discusses some of the key considerations for dermatologists in private practice. Dr Bronfenbrener highlights the importance of financial oversight, saying that financial metrics “should be something that is tracked…...
Considerations for Nocturnal Home Hemodialysis
9+ hour, 28+ min ago (482+ words) What is the most compelling evidence supporting the use of nocturnal home hemodialysis—particularly for cardiovascular health, volume control, and quality of life? Nocturnal therapy is usually provided four to six times a night with average 5 or 6 to 10 hours for…...
The Real Barriers to HER2-Low Breast Cancer Care
9+ hour, 1+ min ago (85+ words) Docwire News The Real Barriers to HER2-Low Breast Cancer Care While HER2 testing rates in breast cancer are already high, Dr. Jessica Paulus, of Ontada, reveals a more subtle challenge: how clinicians interpret and act on those results, particularly in the…...
Talking Trials With Lazarus Award Winner Ron Wald
9+ hour, 28+ min ago (925+ words) Michael Lazarus Award winner Ron Wald, MD,of St. Michael’s Hospital in Toronto, Canada, joined Joel Topf, MD,of Nephrology Times at the 2026 National Kidney Foundation (NKF) Spring Clinical Meetings to discuss dialysis and recent clinical trials. This transcript was…...
Ustekinumab May Fill Unmet Need for Pediatric Ulcerative Colitis
9+ hour, 33+ min ago (290+ words) Jeffrey Hyams, MD, of the University of Connecticut and Connecticut Children’s Hospital in Hartford, Connecticut, shares results from the UNIFI JR trial evaluating ustekinumab in pediatric patients with ulcerative colitis who did not respond to conventional therapies. From these results…...
USP9X: A Potential New Way to Sensitize Tumors to ADC Therapy
9+ hour, 1+ min ago (213+ words) By performing whole‑genome CRISPR screens in heterogeneous co‑cultures, Dr. Kornelia Polyak et al. identified genes that sensitize HER2‑low cells to T‑DXd. In this segment, Dr. Polyak focuses on USP9X and ABCC1, explaining why USP9X stood out as a promising and…...